Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations. Results From the COBIS (Coronary Bifurcation Stenting) Registry

Journal of the American College of Cardiology

Volumn 55, Issue 16, 2010, Pages 1743-1750

  Song, Young Bin ^a   Hahn, Joo Yong ^a   Choi, Seung Hyuk ^a   Choi, Jin Ho ^a   Lee, Sang Hoon ^a   Jeong, Myung Ho ^b   Kim, Hyo Soo ^c   Seong, In Whan ^d   Yang, Ju Young ^e   Rha, Seung Woon ^f   Jang, Yangsoo ^g   Yoon, Jung Han ^h   Tahk, Seung Jea ⁱ   Seung, Ki Bae ^j   Park, Seung Jung ^k   Gwon, Hyeon Cheol ^a  

^a Samsung Medical Center   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Chungnam National University College of Medicine   (South Korea)

^e National Health Insurance Corporation   (South Korea)

^f Korea University Ansan Hospital   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Wonju Severance Christian Hospital   (South Korea)

ⁱ Ajou University School of Medicine   (South Korea)

^j The Catholic University of Korea   (South Korea)

^k University of Ulsan   (South Korea)

more..

Author keywords

angioplasty; bifurcation lesions; paclitaxel eluting stent; sirolimus eluting stent

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY BIFURCATION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KOREA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; REGISTRIES; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77950581223     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.02.008     Document Type: Article

References (21)

1. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
3. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
4. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
5. Morice M.C., Colombo A., Meier B., et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions. The REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904
6. Cosgrave J., Melzi G., Corbett S., et al. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 49 (2007) 2320-2328
7. Simonton C.A., Brodie B., Cheek B., et al. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry-STENT Group. J Am Coll Cardiol 50 (2007) 1214-1222
8. Hoye A., van Mieghem C.A., Ong A.T., et al. Treatment of de novo bifurcation lesions: comparison of sirolimus- and paclitaxel-eluting stents. EuroIntervention 1 (2005) 24-30
9. Pan M., Suarez de Lezo J., Medina A., et al. Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. Am Heart J 153 (2007) 15
10. Latib A., Cosgrave J., Godino C., et al. Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations. Am Heart J 156 (2008) 745-750
11. Medina A., Suarez de Lezo J., and Pan M. [A new classification of coronary bifurcation lesions]. Rev Esp Cardiol 59 (2006) 183
12. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
13. Breslow N. Covariance adjustment of relative-risk estimates in matched studies. Biometrics 38 (1982) 661-672
14. Colombo A., Moses J.W., Morice M.C., et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 109 (2004) 1244-1249
15. Tanabe K., Hoye A., Lemos P.A., et al. Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. Am J Cardiol 94 (2004) 115-118
16. Colombo A., and Chieffo A. Drug-eluting stent update 2007. Part III: technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease). Circulation 116 (2007) 1424-1432
17. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 (2005) 165-171
18. Kim Y.H., Park S.W., Lee S.W., et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 114 (2006) 2148-2153
19. Mehilli J., Dibra A., Kastrati A., Pache J., Dirschinger J., and Schomig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27 (2006) 260-266
20. Daemen J., Garcia-Garcia H.M., Kukreja N., et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 28 (2007) 26-32
21. Mahmud E., Bromberg-Marin G., Palakodeti V., Ang L., Creanga D., and Demaria A.N. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol 51 (2008) 2385-2395